At the time of writing, Replimune Group Inc [REPL] stock is trading at $10.0, up 2.99%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The REPL shares have gain 6.50% over the last week, with a monthly amount glided 2.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Replimune Group Inc [NASDAQ: REPL] stock has seen the most recent analyst activity on November 03, 2025, when BMO Capital Markets upgraded its rating to a Market Perform but kept the price target unchanged to $11 for it. Previously, H.C. Wainwright upgraded its rating to Buy on October 27, 2025, and kept the price target unchanged to $12. On October 20, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $18 on the stock. Piper Sandler upgraded its rating to a Overweight but stick to its price target of $13 on October 20, 2025. Leerink Partners upgraded its rating to a Outperform but $13 remained the price target by the analyst firm on October 20, 2025. JP Morgan upgraded its rating to Neutral for this stock on October 20, 2025. In a note dated September 19, 2025, JP Morgan downgraded an Underweight rating on this stock.
For the past year, the stock price of Replimune Group Inc fluctuated between $2.68 and $14.80. Currently, Wall Street analysts expect the stock to reach $13.67 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $10.0 at the most recent close of the market. An investor can expect a potential return of 36.7% based on the average REPL price forecast.
Analyzing the REPL fundamentals
Gross Profit Margin for this corporation currently stands at -1.92% with Operating Profit Margin at -200.19%, Pretax Profit Margin comes in at -190.05%, and Net Profit Margin reading is -190.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.69 and Total Capital is -0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.15 points at the first support level, and at 8.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.06, and for the 2nd resistance point, it is at 12.11.
Ratios To Look Out For
It is important to note that Replimune Group Inc [NASDAQ:REPL] has a current ratio of 6.31. Also, the Quick Ratio is 6.31, while the Cash Ratio stands at 1.63.
Transactions by insiders
Recent insider trading involved Sushil Patel, Chief Strategy Officer, that happened on Dec 02 ’25 when 10000.0 shares were purchased. Chief Commercial Officer, Sarchi Christopher completed a deal on Nov 17 ’25 to sell 5208.0 shares. Meanwhile, Chief Medical Officer Xynos Konstantinos sold 7248.0 shares on Nov 17 ’25.
